- Merck’s Patritumab Deruxtecan shows significant improvement in progression-free survival over doublet chemotherapy for advanced EGFR-mutated non-small cell lung cancer in Phase 3 HERTHENA-Lung02 trial.
Tue Sep 17 09:02:07 -2024 UTC– Merck & Co. announced that Patritumab Deruxtecan showed significant progress in patients with advanced EGFR-mutated lung cancer in a Phase 3 trial.
Merck & Co. announced that its new drug, Patritumab Deruxtecan, has shown significant improvement in treating patients with advanced lung cancer. This was observed in a large Phase 3 clinical trial focused on patients with a specific type of lung cancer that has a mutation in the EGFR gene. The drug outperformed the current standard chemotherapy in helping patients live longer without their disease worsening.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business